The Hype
HYPE: Taking zinc lozenges when a cold starts helps it end sooner.
But what does the evidence actually show?
Zinc may shorten an ongoing cold, but studies and products differ. Uncertain benefits must be weighed against nausea and unpleasant taste.
The Claim
The strongest fair version is that a particular oral zinc lozenge, started early in a naturally acquired cold, could shorten the illness. It is a treatment claim about a specific product and schedule. It does not establish that a daily zinc tablet prevents infection, or that every supplement containing zinc has the same effect.
The proposed action involves contact with the mouth and throat as a lozenge dissolves. That differs from simply swallowing a capsule to meet a nutritional requirement. Zinc's normal role in immune function makes the idea plausible, but plausibility still needs a successful comparison against placebo in people with colds. [5]
What the Evidence Says
The largest recent review finds a possible benefit
The 2024 Cochrane review included 34 prevention or treatment studies, involving 8,526 participants overall. The duration estimate came from eight treatment studies with 972 people. Across those studies, zinc was associated with colds ending an average 2.37 days sooner; the confidence interval ranged from about half a day to four days. The authors judged this low-certainty evidence. [1]
That estimate pooled oral lozenges and intranasal formulations, with substantial differences between studies. It cannot promise two days saved with a shop-bought lozenge. Overall symptom severity remained uncertain. [1]
Earlier synthesis points in a similar direction
A 2021 review of 28 adult trials also found symptoms resolving about two days earlier, but rated that duration evidence very low in certainty. It considered broader acute respiratory infections and included different delivery routes. Its authors could not establish which formulation or dose was best. [2]
These reviews draw on overlapping research. Similar conclusions are reassuring about the presence of a signal, but they are not two entirely independent sets of experiments. Nor should a broad respiratory-infection estimate be presented as an exact prediction for one person's ordinary cold.
Positive and negative trials both matter
In a 2008 double-blind trial, 50 adults enrolled within 24 hours of symptom onset. They used a 13.3 mg zinc acetate lozenge or placebo every two to three waking hours. Mean cold duration was 4.0 days with zinc and 7.1 days with placebo, and several symptom measures improved. This was a striking result, but a small study of one regimen. [3]
A preregistered 2020 trial tested a commercially available zinc acetate lozenge. Participants were given study packs in advance so they could begin promptly if ill. Eighty-seven people contributed to the primary cold analysis. The planned schedule supplied 78 mg elemental zinc daily for up to five days, yet recovery was not significantly faster than with placebo over ten days. [4]
These findings do not neatly establish that acetate works or fails. They show why the salt name alone is an inadequate guarantee. Duration of treatment, the actual lozenge and study population can matter, and the negative trial could not resolve which explanation accounted for its result. [4]
The Catch
Symptoms and taste complicate the experiments
Cold recovery is usually recorded by participants. An unpleasant-tasting active treatment may reveal the assigned group, potentially affecting reporting. The 2020 trial tried to camouflage the taste in the placebo, yet adverse effects were more common with zinc. Thirty-seven per cent of zinc users reported none, compared with 69% of placebo users. [4]
Cochrane found that treatment probably increased non-serious adverse effects. Many trials also had unclear or high risk of bias. Those limitations remain despite a positive average. [1]
Research doses are not routine nutrition advice
For UK readers, NHS advice is to avoid more than 25 mg daily from zinc supplements unless a doctor advises otherwise. Several cold-trial regimens exceed that amount. This is a reason to seek professional advice, not copy a study dose. [8]
Many tested regimens exceed the US adult upper intake level of 40 mg zinc daily. NIH explains that excessive zinc can cause nausea and gastric upset; taking 50 mg or more for weeks can impair copper absorption. The upper level concerns usual intake and does not substitute for clinical supervision of a treatment. Do not turn a short experimental regimen into a daily winter habit. [5]
Oral zinc can interact with medicines, including some antibiotics and penicillamine. Products used inside the nose have a separate risk: NCCIH warns that intranasal zinc has been linked to potentially permanent loss of smell. Evidence about oral lozenges is not a reason to use a zinc nasal gel or spray. [6]
What This Means for You
A zinc lozenge is an option to discuss with a pharmacist if the possibility of a shorter cold matters to you. Ask about the exact product, safe duration and your other medicines. Check the amount of elemental zinc across all supplements rather than adding lozenges on top of an existing zinc stack.
Expect uncertainty: neither a pleasant taste nor an acetate label establishes that a product matches a successful trial. The 2021 review found limited tolerability for some users and no clear winner among formulations. [2]
Rest, fluids and suitable symptom relief remain useful. Seek advice for worsening illness, chest pain or breathlessness, or if you have a weakened immune system or significant long-term condition. A supplement trial is not a reason to assume every respiratory illness is an uncomplicated cold. [7]
The practical verdict: zinc has a credible treatment signal, with real uncertainty about the product and benefit. It deserves measured expectations rather than a guaranteed two-day recovery claim.
Scientific Sources
1. Nault D et al. (2024). Zinc for prevention and treatment of the common cold. Cochrane Database of Systematic Reviews. CD014914.
Read the original source ↗2. Hunter J et al. (2021). Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials. BMJ Open 11:e047474.
Read the original source ↗3. Prasad AS et al. (2008). Duration and severity of symptoms and levels of inflammatory markers in patients with common cold treated with zinc acetate. Journal of Infectious Diseases 197:795–802.
Read the original source ↗4. Hemilä H et al. (2020). Zinc acetate lozenges for the treatment of the common cold: a randomised controlled trial. BMJ Open 10:e031662.
Read the original source ↗5. NIH Office of Dietary Supplements. Zinc: Health Professional Fact Sheet.
Read the original source ↗6. NCCIH. Colds, Flu, and Complementary Health Approaches: Usefulness and Safety.
Read the original source ↗7. NHS. Common cold.
Read the original source ↗8. NHS. Vitamins and minerals: Others — Zinc.
Read the original source ↗Evidence reviewed: 10 November 2026
This is a targeted editorial review, not an exhaustive systematic review. Available full texts, verified research abstracts and authoritative guidance were considered; inaccessible full texts were not independently assessed. Evidence vs Hype provides education, not individual diagnosis or treatment.
Featured artwork: editorial illustration, not a study image or result.
